Log in

Relevant bibliographies by topics / Primary cytoreductive surgery / Journal articles

To see the other types of publications on this topic, follow the link: Primary cytoreductive surgery.

Journal articles on the topic 'Primary cytoreductive surgery'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Primary cytoreductive surgery.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Gerestein, Cornelis G., Dirkina W. van der Spek, Marinus J. Eijkemans, Jeanette Bakker, Geertruida S. Kooi, and Curt W. Burger. "Prediction of Residual Disease After Primary Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Accuracy of Clinical Judgment." International Journal of Gynecologic Cancer 19, no. 9 (2009): 1511–15. http://dx.doi.org/10.1111/igc.0b013e3181bf82be.

Full text

Abstract:

Objectives:Treatment of patients with an advanced-stage epithelial ovarian cancer (EOC) is based on cytoreductive surgery and platinum-based chemotherapy. Amount of residual disease after primary cytoreductive surgery is an important prognostic factor.The objectives of the present study were to evaluate the accuracy and reproducibility of preoperative clinical judgment of residual disease after primary cytoreductive surgery and to compare the predictive performance of the offhand assessment to the predictive performance of prediction models.Materials and Methods:Fifteen observers (5 gynecologi

APA, Harvard, Vancouver, ISO, and other styles

2

Li, Yiu-Tai, Szu-Ting Yang, and Peng-Hui Wang. "Primary cytoreductive surgery or interval cytoreductive surgery." Taiwanese Journal of Obstetrics and Gynecology 63, no. 6 (2024): 811–13. http://dx.doi.org/10.1016/j.tjog.2024.09.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Dottino, Joseph A., Weiguo He, Charlotte C. Sun, et al. "National trends in bowel and upper abdominal procedures in ovarian cancer surgery." International Journal of Gynecologic Cancer 30, no. 8 (2020): 1195–202. http://dx.doi.org/10.1136/ijgc-2020-001243.

Full text

Abstract:

ObjectivesIn the United States, trends in the initial treatment approach for ovarian cancer reflect a shift in paradigm toward the increased use of neoadjuvant chemotherapy and interval cytoreductive surgery. The aim of this study was to evaluate the trends in surgical cytoreductive procedures in ovarian cancer patients who underwent either primary or interval cytoreductive surgery.MethodsThis retrospective, population-based study examined patients with stage III/IV ovarian cancer diagnosed between January 2000 and December 2013 identified using SEER-Medicare. Small or large bowel resection, o

APA, Harvard, Vancouver, ISO, and other styles

4

Csikos, Csaba, Péter Czina, Szabolcs Molnár, Anna Rebeka Kovács, Ildikó Garai, and Zoárd Tibor Krasznai. "Predicting Complete Cytoreduction with Preoperative [18F]FDG PET/CT in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis." Diagnostics 14, no. 16 (2024): 1740. http://dx.doi.org/10.3390/diagnostics14161740.

Full text

Abstract:

The cornerstone of ovarian cancer treatment is complete surgical cytoreduction. The gold-standard option in the absence of extra-abdominal metastases and intra-abdominal inoperable circumstances is primary cytoreductive surgery (CRS). However, achieving complete cytoreduction is challenging, and only possible in a selected patient population. Preoperative imaging modalities such as [18F]FDG PET/CT could be useful in patient selection for cytoreductive surgery. In our systematic review and meta-analysis, we aimed to evaluate the role of preoperative [18F]FDG PET/CT in predicting complete cytore

APA, Harvard, Vancouver, ISO, and other styles

5

Memarzadeh, S., S. B. Lee, J. S. Berek, and R. Farias-Eisner. "CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer." International Journal of Gynecologic Cancer 13, no. 2 (2003): 120–24. http://dx.doi.org/10.1136/ijgc-00009577-200303000-00003.

Full text

Abstract:

The utility of preoperative CA125 to predict optimal primary tumor cytoreduction in patients with advanced (stages IIIC and IV) epithelial ovarian cancer is controversial. In this paper, we retrospectively review patients with stage IIIC and IV epithelial ovarian cancer who underwent primary cytoreductive surgery from 1989 to 2001. Ninety-nine patients were identified and included in the analysis. All patients had preoperative CA125 levels measured. Operative and pathology reports were reviewed. Optimal cytoreduction was defined as largest volume of residual disease < 1 cm in maximal dimens

APA, Harvard, Vancouver, ISO, and other styles

6

Koole, Simone, Ruby van Stein, Karolina Sikorska, et al. "Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial." International Journal of Gynecologic Cancer 30, no. 6 (2020): 888–92. http://dx.doi.org/10.1136/ijgc-2020-001231.

Full text

Abstract:

BackgroundThe addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive surgery. The effect of HIPEC remains undetermined in patients who are candidates for primary cytoreductive surgery.Primary objectiveThe primary objective is to evaluate the effect of HIPEC on overall survival in patients with FIGO stage III epithelial ovarian cancer who are treated with primary cytoreductive surgery resulting in no residual disease,

APA, Harvard, Vancouver, ISO, and other styles

7

Nam, J. H., Y. M. Kim, M. H. Jung, et al. "Primary peritoneal carcinoma: experience with cytoreductive surgery and combination chemotherapy." International Journal of Gynecologic Cancer 16, no. 1 (2006): 23–28. http://dx.doi.org/10.1136/ijgc-00009577-200601000-00004.

Full text

Abstract:

The objective of this study was to review the clinical outcome and prognosis of patients with primary peritoneal carcinoma (PPC) treated with cytoreductive surgery and combination chemotherapy. We retrospectively reviewed the charts of 27 patients with histologically confirmed PPC, treated between March 1990 and February 2004 at Asan Medical Center, South Korea. The review included demographic data, pathologic findings, treatments, and outcomes. The mean age of the 27 patients was 57.5 ± 7.2 years, and the rate of optimal cytoreduction was 70.4%. Seven patients had stage IIIB, 17 had stage III

APA, Harvard, Vancouver, ISO, and other styles

8

Wright, Alexi A., Kari Bohlke, Deborah K. Armstrong, et al. "Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline." Journal of Clinical Oncology 34, no. 28 (2016): 3460–73. http://dx.doi.org/10.1200/jco.2016.68.6907.

Full text

Abstract:

Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer. Methods The Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature. Results Four phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are no

APA, Harvard, Vancouver, ISO, and other styles

9

Lūža, Tomas, Agnė Ožalinskaitė, and Vilius Rudaitis. "The rate and role of diaphragmatic peritonectomy in optimal cytoreduction in patients with advanced stage ovarian cancer: a prospective study of 100 patients." Acta medica Lituanica 21, no. 1 (2014): 1–7. http://dx.doi.org/10.6001/actamedica.v21i1.2882.

Full text

Abstract:

Background. Diaphragmatic peritoneal metastasis by advanced epithelial ovarian cancer is a very common holdback precluding optimal cytoreduction. The aim of this study was to determine the rate of diaphragmatic peritonectomy during optimal cytoreductive surgery and its role in postoperative morbidity and survival in patients with advanced ovarian cancer. Materials and methods. 100 consecutive patients with advanced epithelial ovarian cancer underwent cytoreductive surgery and were followed up prospectively (January 2009 – March 2014). Characteristics of surgery, rate of diaphragmatic periton

APA, Harvard, Vancouver, ISO, and other styles

10

Gockley, Allison Ann, Stephen Fiascone, Katherine Hicks Courant, et al. "Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma." International Journal of Gynecologic Cancer 29, no. 3 (2019): 585–92. http://dx.doi.org/10.1136/ijgc-2018-000154.

Full text

Abstract:

ObjectiveThere are limited data on clinical outcomes of patients with advanced-stage epithelial ovarian cancer who require ostomy formation at the time of either primary cytoreductive surgery or interval cytoreductive surgery. The objective of this study was to evaluate patients undergoing bowel surgery and ostomy formation after primary or interval surgery.MethodsPatients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV epithelial ovarian cancer who underwent cytoreductive surgery between January 2010 and December 2014 were identified retrospectively. Patients w

APA, Harvard, Vancouver, ISO, and other styles

11

Abitbol, Jeremie, Walter Gotlieb, Ziggy Zeng, et al. "Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy." International Journal of Gynecologic Cancer 29, no. 9 (2019): 1341–47. http://dx.doi.org/10.1136/ijgc-2019-000413.

Full text

Abstract:

IntroductionWith the rapid uptake of robotic surgery in surgical oncology, its use in the treatment of epithelial ovarian cancers is being evaluated. Complete cytoreduction represents the goal of surgery either at primary cytoreduction or after neoadjuvant chemotherapy in the setting of interval cytoreduction. In selected patients, the extent of disease would enable minimally invasive surgery. The objective of this study was to evaluate the impact of introducing robotic surgery for interval cytoreduction of selected patients with stage III–IV ovarian cancer.MethodsAll patients who underwent su

APA, Harvard, Vancouver, ISO, and other styles

12

Luyckx, Mathieu, Eric Leblanc, Thomas Filleron, et al. "Maximal Cytoreduction in Patients With FIGO Stage IIIC to Stage IV Ovarian, Fallopian, and Peritoneal Cancer in Day-to-Day Practice: A Retrospective French Multicentric Study." International Journal of Gynecologic Cancer 22, no. 8 (2012): 1337–43. http://dx.doi.org/10.1097/igc.0b013e31826a3559.

Full text

Abstract:

ObjectivesTo evaluate the outcome of maximal cytoreductive surgery in patients with stage IIIC to stage IV ovarian, tubal, and peritoneal cancer regarding overall survival (OS) and disease-free survival (DFS).Materials and MethodsFive hundred twenty-seven patients with stage IIIC (peritoneal) and stage IV (pleural) ovarian, fallopian tube, and peritoneal carcinoma underwent surgery between January 2003 and December 2007 in 7 gynecologic oncology centers in France. Patients undergoing primary and interval debulking surgery were included, whichever the number of chemotherapy cycles. The extent o

APA, Harvard, Vancouver, ISO, and other styles

13

Look, M., D. Chang, and P. H. Sugarbaker. "Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum." International Journal of Gynecologic Cancer 13, no. 6 (2003): 764–70. http://dx.doi.org/10.1136/ijgc-00009577-200311000-00006.

Full text

Abstract:

The aim of this study was to review the long-term results of cytoreductive surgery in the treatment of advanced primary and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Our goal was to identify clinical factors by which to select patients likely to benefit from a comprehensive management plan. Clinical data of 28 females who underwent surgery were retrieved from a prospective database. Major cytoreductive procedures were possible in 25 patients. Heated intraoperative or early postoperative intraperitoneal chemotherapy was also used where appropriate. T

APA, Harvard, Vancouver, ISO, and other styles

14

Srougi, Victor, Irina Bancos, Marilyne Daher, et al. "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients’ Survival." Journal of Clinical Endocrinology & Metabolism 107, no. 4 (2021): 964–71. http://dx.doi.org/10.1210/clinem/dgab865.

Full text

Abstract:

Abstract Context The role of cytoreduction of adrenocortical carcinoma (ACC) remains poorly understood. Objective To analyze the impact of cytoreductive surgery of the primary tumor in patients with metastatic ACC. Design and Setting We performed a multicentric, retrospective paired cohort study comparing the overall survival (OS) in patients with metastatic ACC who were treated either with cytoreductive surgery (CR group) or without cytoreductive surgery (no-CR group) of the primary tumor. Data were retrieved from 9 referral centers in the American-Australian-Asian Adrenal Alliance collaborat

APA, Harvard, Vancouver, ISO, and other styles

15

Look, M., D. Chang, and P. H. Sugarbaker. "Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum." International Journal of Gynecologic Cancer 14, no. 1 (2004): 35–41. http://dx.doi.org/10.1136/ijgc-00009577-200401000-00004.

Full text

Abstract:

The aim of this study was to review the long-term results of cytoreductive surgery in the treatment of advanced primary and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Our goal was to identify clinical factors by which to select patients likely to benefit from a comprehensive management plan.Clinical data of 28 females who underwent surgery were retrieved from a prospective database. Major cytoreductive procedures were possible in 25 patients. Heated intraoperative or early postoperative intraperitoneal chemotherapy was also used where appropriate. Th

APA, Harvard, Vancouver, ISO, and other styles

16

CHEN, L., L. A. LEARMAN, V. WEINBERG, and C. B. POWELL. "Discordance between beliefs and recommendations of gynecologic oncologists in ovarian cancer management*." International Journal of Gynecologic Cancer 14, no. 6 (2004): 1055–62. http://dx.doi.org/10.1136/ijgc-00009577-200411000-00001.

Full text

Abstract:

PurposeThe purpose of this study was to determine how physician experts make decisions for clinical scenarios in ovarian cancer and describe a profile of factors reported to influence treatment decisions.MethodsA questionnaire was sent to Full Members of the Society of Gynecologic Oncologists regarding surgery and chemotherapy for scenarios of primary and recurrent ovarian cancer.ResultsIn a scenario of primary presentation, 94% of respondents chose a treatment of tumor resection over chemotherapy. Despite the preference for surgery in a clinical scenario, 50% agreed with a statement that neoa

APA, Harvard, Vancouver, ISO, and other styles

17

Zivanovic, O., D. S. Chi, E. L. Eisenhauer, et al. "A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal, and peritoneal carcinoma." Journal of Clinical Oncology 25, no. 18_suppl (2007): 5572. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.5572.

Full text

Abstract:

5572 Background: We previously reported that preoperative CA-125 may predict primary cytoreductive outcome in patients (pts) with stage III ovarian carcinoma. We performed a contemporary analysis of the ability of preop CA-125 to predict cytoreductive outcome in advanced ovarian, tubal and peritoneal carcinoma. Methods: In 1/01, we initiated a programmatic change in our primary surgical approach to advanced gynecologic malignancies using extensive upper abdominal procedures to achieve maximal cytoreduction. We reviewed the records of all pts with advanced ovarian, tubal or peritoneal carcinoma

APA, Harvard, Vancouver, ISO, and other styles

18

Muallem, Mustafa Zelal, Luisa Kluge, Ahmad Sayasneh, et al. "A Promising Approach for Primary Cytoreductive Surgery for Advanced Ovarian Cancer: Survival Outcomes and Step-by-Step Description of Total Retroperitoneal en-Bloc Resection of Multivisceral-Peritoneal Packet (TROMP)." Journal of Personalized Medicine 12, no. 6 (2022): 899. http://dx.doi.org/10.3390/jpm12060899.

Full text

Abstract:

(1) Background: A complete tumor resection during primary cytoreductive surgery has been reported to be the most important and perhaps the only independent prognostic factor in advanced ovarian cancers. The goal of complete cytoreduction needs to be weighed against the potential morbidities and long-term survival outcomes. (2) Methods: in this retrospective analysis of a prospectively obtained database, 208 consecutive patients with advanced ovarian cancer who underwent a conventional primary cytoreductive surgery (150 patients) or TROMP technique (58 patients) were included. Progression-free

APA, Harvard, Vancouver, ISO, and other styles

19

Kim, Ji Hyun, Eun Taeg Kim, Se Ik Kim, et al. "Prognostic Role of CA-125 Elimination Rate Constant (KELIM) in Patients with Advanced Epithelial Ovarian Cancer Who Received PARP Inhibitors." Cancers 16, no. 13 (2024): 2339. http://dx.doi.org/10.3390/cancers16132339.

Full text

Abstract:

Background: This multicenter retrospective study aimed to investigate the prognostic value of the CA-125 elimination rate constant K (KELIM) in EOC patients who received platinum-based chemotherapy followed by PARP inhibitors, in either upfront or interval treatment settings. Methods: Between July 2019 and November 2022, we identified stage III–IV EOC patients who underwent primary or interval cytoreductive surgery and received olaparib or niraparib. Individual KELIM values were assessed based on validated kinetics and classified into favorable and unfavorable cohorts. Results: In a study of 2

APA, Harvard, Vancouver, ISO, and other styles

20

Kumar, D. Suresh, S. Navin Noushad, and M. P. Viswanathan. "Pelvic lymphadenectomy as a component of interval cytoreduction for ovarian cancer: is there a benefit? A pilot study." International Journal of Research in Medical Sciences 5, no. 3 (2017): 821. http://dx.doi.org/10.18203/2320-6012.ijrms20170515.

Full text

Abstract:

Background: Management strategy in ovarian cancer includes a combination of cytoreductive surgery and chemotherapy. Interval cytoreductive surgery has been shown to be oncologically non-inferior to primary cytoreduction with the additional benefit of reduced morbidity. Lymphadenectomy as a component of cytoreductive surgery has been controversial with an unproven therapeutic benefit.Methods: Records of patients with a histological diagnosis of ovarian cancer and treated with interval cytoreduction were evaluated. Disease related, pathological and treatment data collected for analysis.Results:

APA, Harvard, Vancouver, ISO, and other styles

21

Polterauer, Stephan, Ignace Vergote, Nicole Concin, et al. "Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA–IV: Analysis of the OVCAD Data." International Journal of Gynecologic Cancer 22, no. 3 (2012): 380–85. http://dx.doi.org/10.1097/igc.0b013e31823de6ae.

Full text

Abstract:

ObjectiveThe objective of the study was to evaluate the prognostic impact of residual tumor size after cytoreductive surgery in patients with epithelial ovarian cancer.MethodsIn this prospective, multicenter study, 226 patients with epithelial ovarian cancer (International Federation of Gynecology and Obstetrics stages IIA–IV) were included. Patients were treated with cytoreductive surgery and adjuvant platinum-based chemotherapy. Univariate and multivariable survival analyses were performed to investigate the impact of residual tumor size on progression-free and overall survival.ResultsIn 69.

APA, Harvard, Vancouver, ISO, and other styles

22

Lyons, Yasmin A., Henry D. Reyes, Megan E. McDonald, et al. "Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy." International Journal of Gynecologic Cancer 30, no. 6 (2020): 845–52. http://dx.doi.org/10.1136/ijgc-2019-001124.

Full text

Abstract:

ObjectiveIn previous studies, neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary cytoreductive surgery as initial treatment for advanced epithelial ovarian cancer. Our study aimed to compare surgical and survival outcomes between the two treatments in a large national database.MethodsData were extracted from the National Cancer Database from January 2004 to December 2015. Patients with FIGO (International Federation of Gynecologists and Obstetricians) stage III-IV epithelial ovarian cancer and known sequence of treatment were included: primary cytoreduc

APA, Harvard, Vancouver, ISO, and other styles

23

van Stein, Ruby M., Simone N. Koole, Karolina Sikorska, et al. "Primary cytoreductive surgery with or without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: The OVHIPEC-2 trial in progress." Journal of Clinical Oncology 38, no. 15_suppl (2020): TPS6100. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps6100.

Full text

Abstract:

TPS6100 Background: The addition of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive surgery due to extensive intraperitoneal disease. The effect of HIPEC remains undetermined in patients who are eligible for primary cytoreductive surgery. We hypothesize that the addition of HIPEC to a complete or near-complete (residual disease ≤2.5 mm) primary cytoreductive surgery improves overall survival in patients with FIGO stage III

APA, Harvard, Vancouver, ISO, and other styles

24

Reuss, Alexander, Andreas du Bois, Philipp Harter, et al. "TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7)." International Journal of Gynecologic Cancer 29, no. 8 (2019): 1327–31. http://dx.doi.org/10.1136/ijgc-2019-000682.

Full text

Abstract:

BackgroundPrimary cytoreductive surgery followed by chemotherapy has been considered standard management for patients with advanced ovarian cancer over decades. An alternative approach of interval debulking surgery following neoadjuvant chemotherapy was subsequently reported by two randomized phase III trials (EORTC‐GCG, CHORUS), which were criticized owing to important limitations, especially regarding the rate of complete resection.Primary ObjectiveTo clarify the optimal timing of surgical therapy in advanced ovarian cancer.Study HypothesisPrimary cytoreductive surgery is superior to interva

APA, Harvard, Vancouver, ISO, and other styles

25

Shrestha Prajapati, Shristee, Anisha Shrestha, Usha Bade Shrestha, et al. "Primary Cytoreductive Surgery versus Neoadjuvant Chemotherapy followed by Interval Cytoreductive Surgery for Advanced Epithelial Ovarian Cancer: A Retrospective Cohort Study." Nepalese Journal of Cancer 7, no. 1 (2023): 33–39. http://dx.doi.org/10.3126/njc.v7i1.60019.

Full text

Abstract:

Introduction: Epithelial ovarian cancer (EOC) represents about two-thirds of ovarian malignancies and usually presents with advanced disease. Primary cytoreductive (PCR) surgery is known to be the cornerstone of treatment of advanced EOC, but it might not always be feasible to obtain optimal cytoreduction. Neoadjuvant chemotherapy (NACT) has been proposed as an alternative approach. This study aims to compare the survival of patients, post-operative morbidity and the extent of cytoreduction that was achieved among the two treatment groups. Methods: A retrospective cohort study was done in Bhak

APA, Harvard, Vancouver, ISO, and other styles

26

MARTÍNEZ-SAÍD, H., D. G. RINCÓN, M. M. MONTES DE OCA, G. C. RUIZ, J. L. A. PONCE, and C. M. LÓPEZ-GRANIEL. "Predictive factors for irresectability in advanced ovarian cancer." International Journal of Gynecologic Cancer 14, no. 3 (2004): 423–30. http://dx.doi.org/10.1136/ijgc-00009577-200405000-00002.

Full text

Abstract:

Despite advances in surgical modalities and chemotherapeutic agents, the 5-year survival for patients with advanced ovarian cancer is barely 40–50%. At the moment, optimally cytoreductive primary surgery is the best option for patients with advanced ovarian cancer. Predictive factors of primary optimum reduction surgery have been described based on imaging studies and tumor markers and based on the premise to knowa priorithe weight and tumor volume, with promising results. A retrospective study was conducted based on the hypothesis that it is feasible to identify those patients not susceptible

APA, Harvard, Vancouver, ISO, and other styles

27

Horvath, Philipp, Can Yurttas, Stefan Beckert, Alfred Königsrainer, and Ingmar Königsrainer. "Twelve-Year Single Center Experience Shows Safe Implementation of Developed Peritoneal Surface Malignancy Treatment Protocols for Gastrointestinal and Gynecological Primary Tumors." Cancers 13, no. 10 (2021): 2471. http://dx.doi.org/10.3390/cancers13102471.

Full text

Abstract:

(1) Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy provide survival benefits to selected patients. We aimed to report our experience and the evolution of our peritoneal surface malignancy program. (2) Methods: From June 2005 to June 2017, 399 patients who underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy at the Tübingen University Hospital were analyzed from a prospectively collected database. (3) Results: Peritoneal metastasis from colorectal cancer was the leading indication (group 1: 28%; group 2: 32%). The median PCI was 15.5 (r

APA, Harvard, Vancouver, ISO, and other styles

28

Lorusso, D., M. Mancini, R. Di Rocco, R. Fontanelli, and F. Raspagliesi. "The Role of Secondary Surgery in Recurrent Ovarian Cancer." International Journal of Surgical Oncology 2012 (2012): 1–6. http://dx.doi.org/10.1155/2012/613980.

Full text

Abstract:

Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30% and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.

APA, Harvard, Vancouver, ISO, and other styles

29

Saikia, Jyoutishman, Babul Bansal, SVS Deo, et al. "Hyperthermic intraperitoneal chemotherapy in locally advanced and recurrent ovarian carcinoma: surgical and oncological outcomes in the Indian public healthcare system." Future Oncology 17, no. 14 (2021): 1761–76. http://dx.doi.org/10.2217/fon-2020-0806.

Full text

Abstract:

This study analyzed the surgical outcomes after initial implementation of a cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) program in government settings in India. Methods: Ovarian cancer patients undergoing cytoreductive surgery and HIPEC from May 2015 to April 2019 were identified from a prospectively maintained database. Treatment characteristics and surgical outcomes were analyzed. Results: The study identified 101 patients. The mean peritoneal cancer index (PCI) was 7 ± 6, with higher PCI scores in primary and recurrent cases. Major morbidities were recorded i

APA, Harvard, Vancouver, ISO, and other styles

30

Bondar, O. V., A. I. Rybin, V. E. Maximovskyi, O. V. Kuznetsova, and S. O. Alieva. "OPTIMISING THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER: AN ANALYSIS OF PRELIMINARY RESULTS." Oncology 25, no. 3 (2023): 222–28. http://dx.doi.org/10.15407/oncology.2023.03.222.

Full text

Abstract:

Summary. Aim: to evaluate surgical complications, side effects of chemotherapy, 1- and 3-year survival in patients with advanced ovarian cancer against the background of the introduction of optimized personalized treatment. Object and methods: for this purpose, a comparative analysis of the results of clinical examination and treatment of 74 patients with primary serous ovarian adenocarcinoma of stages III–IV (FIGO 2015) who were treated at the University Clinic of Odesa National Medical University was conducted. Patients were divided into 2 groups: Group IA — patients with primary ovarian can

APA, Harvard, Vancouver, ISO, and other styles

31

Fader, Amanda Nickles, and Peter G. Rose. "Role of Surgery in Ovarian Carcinoma." Journal of Clinical Oncology 25, no. 20 (2007): 2873–83. http://dx.doi.org/10.1200/jco.2007.11.0932.

Full text

Abstract:

Surgery plays a critical role in the optimal management of all stages of ovarian carcinoma. In apparent early-stage ovarian cancer, a comprehensive surgical evaluation allows stratification of patients into low- and high-risk categories. Low-risk patients may be candidates for fertility-sparing surgery and can safely avoid chemotherapy and be observed. Treatment of patients with high-risk early- or advanced-stage ovarian cancer usually requires a combined modality approach. Although it is well known that epithelial ovarian cancer is moderately chemosensitive, what distinguishes it most from ot

APA, Harvard, Vancouver, ISO, and other styles

32

Arits, A. H. M. M., J. E. G. M. Stoot, A. A. M. Botterweck, F. J. M. E. Roumen, and A. C. Voogd. "Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer." International Journal of Gynecologic Cancer 18, no. 4 (2008): 621–28. http://dx.doi.org/10.1136/ijgc-00009577-200807000-00004.

Full text

Abstract:

The objective is to assess the ability of preoperative serum CA125 levels to identify patients at high risk of suboptimal cytoreductive surgery for epithelial ovarian cancer (EOC). One hundred and thirty-two women diagnosed with EOC between 1998 and 2004, who had serum CA125 levels measured preoperatively and received primary cytoreductive surgery, were retrospectively evaluated. The value of CA125 and patient and disease characteristics to predict suboptimal cytoreduction were determined, and a prognostic scoring system, based on statistically significant variables, was created. Optimal cytor

APA, Harvard, Vancouver, ISO, and other styles

33

Hotouras, Alexander, David Desai, Chetan Bhan, Jamie Murphy, Björn Lampe, and Paul H. Sugarbaker. "Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review." International Journal of Gynecologic Cancer 26, no. 4 (2016): 661–70. http://dx.doi.org/10.1097/igc.0000000000000664.

Full text

Abstract:

BackgroundDespite advances in surgical oncology, most patients with primary ovarian cancer develop a recurrence that is associated with a poor prognosis. The aim of this review was to establish the impact of Heated IntraPEritoneal Chemotherapy (HIPEC) in the overall survival of patients with recurrent ovarian cancer.MethodsA search of PubMed/MEDLINE databases was performed in February 2015 using the terms “recurrent ovarian cancer,” “cytoreductive surgery/cytoreduction,” and “heated/hyperthermic intraperitoneal chemotherapy.” Only English articles with available abstracts assessing the impact

APA, Harvard, Vancouver, ISO, and other styles

34

Jones, Nathaniel L., Ling Chen, Sudeshna Chatterjee, et al. "National Trends in Extended Procedures for Ovarian Cancer Debulking Surgery." International Journal of Gynecologic Cancer 28, no. 1 (2018): 19–25. http://dx.doi.org/10.1097/igc.0000000000001132.

Full text

Abstract:

ObjectivePrimary cytoreduction for ovarian cancer often requires extended radical procedures and is associated with significant morbidity. In 2010, neoadjuvant chemotherapy was shown to have similar survival to primary cytoreduction but with less need for radical surgery. We hypothesized that the increased use of neoadjuvant chemotherapy would decrease the use of radical cytoreductive procedures and thus examined trends in the performance of radical cytoreductive procedures.MethodsWe used the Nationwide Inpatient Sample to determine the annual number of extended procedures (colon, small intest

APA, Harvard, Vancouver, ISO, and other styles

35

Delga, Berenice, Jean-Marc Classe, Gilles Houvenaeghel, et al. "30 Years of Experience in the Management of Stage III and IV Epithelial Ovarian Cancer: Impact of Surgical Strategies on Survival." Cancers 12, no. 3 (2020): 768. http://dx.doi.org/10.3390/cancers12030768.

Full text

Abstract:

Objective: to analyze the evolution of surgical techniques and strategies, and to determine their influence on the survival of patients with stage III or IV epithelial ovarian cancer (EOC). Methods: a retrospective data analysis was performed in two French tertiary cancer institutes. The analysis included clinical information, cytoreductive outcome (complete, optimal and suboptimal), definitive pathology, Overall Survival (OS), and Progression-Free Survival (PFS). Three surgical strategies were compared: Primary Cytoreductive Surgery (PCS), Interval Cytoreductive Surgery (ICS) after three cycl

APA, Harvard, Vancouver, ISO, and other styles

36

Chi, D. S., Y. Sonoda, N. R. Abu-Rustum, et al. "Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma." Journal of Clinical Oncology 24, no. 18_suppl (2006): 5058. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.5058.

Full text

Abstract:

5058 Background: Nomograms have been developed for numerous malignancies to predict a specific individual’s probability of long-term survival based on known prognostic factors. To date, no prediction model has been developed for patients with ovarian cancer. The objective of this study was to develop a nomogram to predict the probability of 4-year survival after primary cytoreductive surgery for bulky stage IIIC ovarian carcinoma. Methods: Nomogram predictor variables included age, tumor grade, histologic type, preoperative platelet count, the presence or absence of ascites, and residual disea

APA, Harvard, Vancouver, ISO, and other styles

37

Ansaloni, Luca. "Cytoreductive surgery in primary advanced epithelial ovarian cancer." World Journal of Obstetrics and Gynecology 2, no. 4 (2013): 116. http://dx.doi.org/10.5317/wjog.v2.i4.116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Berlev, Igor, Anna Sidoruk, Olga Smirnova, et al. "CYTOREDUCTIVE SURGERY WITH PERITONECTOMY IN PATIENTS WITH OVARIAN CANCER: TECHNICAL ASPECTS AND IMMEDIATE RESULTS." Problems in oncology 64, no. 3 (2018): 345–52. http://dx.doi.org/10.37469/0507-3758-2018-64-3-345-352.

Full text

Abstract:

Results of numerous retrospective studies have confirmed that the degree of cytoreduction and the size of the residual tumor after the primary surgery are the most important factors affecting overall life expectancy as well as the time to progression in patients with ovarian cancer (OC). The article presents the immediate results of the first 16 extensive cytoreductive surgeries in advanced OC performed at the Oncogynecology Department of the N.N. Petrov National Medical Research Center of Oncology.

APA, Harvard, Vancouver, ISO, and other styles

39

Tjulandina, A. S., A. A. Rumyantsev, K. Y. Morkhov, V. M. Nechushkina, and S. A. Tjulandin. "RETROSPECTIVE ANALYSIS OF LONG-TERM SURVIVAL OUTCOMES OF PRIMARY CYTOREDUCTION AND NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH OVARIAN CANCER STAGE IIIC–IV." Malignant tumours 8, no. 3 (2018): 86–94. http://dx.doi.org/10.18027/2224-5057-2018-8-3-86-94.

Full text

Abstract:

The choice of treatment strategy in patients with stage IIIC‑IV ovarian cancer (OC) remains the subject of numerous discussions. The reason for this is the unsatisfactory results of randomized trials and the low frequency of primary complete debulking surgery in these studies. We conducted a retrospective analysis to evaluate the survival outcomes in patients with OC stage IIIC–IV (n=314) who underwent treatment between 1995 and 2017. The median progression free survival for primary surgery was 15.6 months, after interval debulking – 11.5 months (p=0.002, HR 0.61: 95 % CI 0.39–0.81). The prima

APA, Harvard, Vancouver, ISO, and other styles

40

Svintsitskiy, V., and A. Rekuta. "Predictive factors of cytoreduction: laparoscopy diagnostic as treatment of choice in patients with advanced forms of serous ovarian cancer." HEALTH OF WOMAN, no. 9(145) (November 30, 2019): 72–75. http://dx.doi.org/10.15574/hw.2019.145.72.

Full text

Abstract:

Ovarian cancer (OC) holds the first place in a structure of mortality among oncogynecology diseases all over the world. Complex approach in treatment of advanced forms of serous ovarian cancer (SOC) (stages III-IV by FIGO) – suggests a combination of surgery and chemotherapy methods – as the world standard. Nowadays, use of operative intervention at the preliminary stage of treatment (primary cytoreduction) is regarded as preferred and contributes to remote therapy results in women, if compared to those patients whose treatment started with the courses of neoajuvant chemotherapy. Nevertheless,

APA, Harvard, Vancouver, ISO, and other styles

41

Sorokin, P. I., D. O. Utkin, M. V. Novozhilov, Z. T. Abduragimova, and S. E. Kulikova. "Remote results of treatment of patients with advanced ovarian cancer after interval and delayed cytoreductive surgery: a retrospective single-center study." Tumors of female reproductive system 21, no. 1 (2025): 68–74. https://doi.org/10.17650/1994-4098-2025-21-1-68-74.

Full text

Abstract:

Background. Neoadjuvant chemotherapy is an option for the treatment of advanced ovarian cancer. The data about optimal chemotherapy cycles before surgery is contradictory. We conducted a retrospective study to evaluate long-term outcomes following interval and delayed cytoreductive surgeries.Aim. To compare long-term outcomes following interval and delayed cytoreductive surgeries.Materials and methods. The study included 115 patients who suffered from advanced ovarian cancer (IIIC–IVB stages) and were operated in Moscow City Oncology Hospital No. 62 after 3–4 (interval cytoreductive surgery; n

APA, Harvard, Vancouver, ISO, and other styles

42

Kryzhanivska, Anna, Roman Hrytsyk, Tetiana Teren, and Yuriy Savchuk. "Role of Computed Tomography in the Diagnosis of Ovarian Cancer." Archive of Clinical Medicine 29, no. 1 (2023): 21–23. http://dx.doi.org/10.21802/acm.2023.1.19.

Full text

Abstract:

Introduction. Malignant formations in the ovaries remain a pressing issue in the field of oncology today. Ovarian cancer occupies one of the leading positions in terms of frequency (7th place) and mortality (4th place). The lack of symptoms during the course of the disease is explained by the fact that cancer cells primarily spread through the abdominal cavity, often leading to late-stage disease diagnosis. The prognosis of the disease depends on the stage of the disease, the level of tumor differentiation, the period of recurrence-free survival, and the size of the residual tumor after surgic

APA, Harvard, Vancouver, ISO, and other styles

43

Cardillo, Nicholas, Eric J. Devor, Silvana Pedra Nobre, et al. "Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer." Cancers 14, no. 14 (2022): 3554. http://dx.doi.org/10.3390/cancers14143554.

Full text

Abstract:

Advanced high-grade serous (HGSC) ovarian cancer is treated with either primary surgery followed by chemotherapy or neoadjuvant chemotherapy followed by interval surgery. The decision to proceed with surgery primarily or after chemotherapy is based on a surgeon’s clinical assessment and prediction of an optimal outcome. Optimal and complete cytoreductive surgery are correlated with improved overall survival. This clinical assessment results in an optimal surgery approximately 70% of the time. We hypothesize that this prediction can be improved by using biological tumor data to predict optimal

APA, Harvard, Vancouver, ISO, and other styles

44

Khan, Mst Farhana Tarannum Khan, Chowdhury Shamima Sultana, Nasrin Hossain, Begum Rokeya Anwar, Mahenaj Afroz, and Salma Akter Walida. "Association of Pre-operative Serum Albumin Level with Post-operative Complications in Patients Undergoing Primary Cytoreductive Surgery for Epithelial Ovarian Carcinoma (EOC)." Bangladesh Medical Research Council Bulletin 50, no. 1 (2024): 15–24. http://dx.doi.org/10.3329/bmrcb.v50i1.68856.

Full text

Abstract:

Background: Epithelial ovarian carcinoma (EOC) is the most lethal of all the gynaecological malignancies. Primary cytoreductive surgery is one of the mainstays in the management of women with epithelial ovarian carcinoma. Because of the silent nature of the condition, most patients present in advanced stage of the disease and malnutrition is common in them. Thus, preoperative evaluation of serum albumin in patients with EOC in regards to primary cytoreductive surgery seems to be of particular importance. Objective: The aim of this study was to evaluate the association between preoperative seru

APA, Harvard, Vancouver, ISO, and other styles

45

Bridges, J. E., Y. Leung, I. G. Hammond, and A. J. Mccartney. "En bloc resection of epithelial ovarian tumors with concomitant rectosigmoid colectomy: the KEMH experience." International Journal of Gynecologic Cancer 3, no. 4 (1993): 199–202. http://dx.doi.org/10.1046/j.1525-1438.1993.03040199.x.

Full text

Abstract:

Between the years 1984 and 1988, 43 patients with bulky advanced stage epithelial ovarian carcinoma underwent en bloc pelvic resection with excision of the rectosigmoid colon as part of their primary cytoreductive surgery. Optimal cytoreduction was accomplished in over 70% of cases, and all women had complete debulking of their pelvic tumor. Primary anastomosis of the bowel was feasible in all cases and only two covering colostomies were performed. There were no postoperative leaks or fistulas. The postoperative morbidity was reflected by a mean postoperative hospital stay of 16 days. Our resu

APA, Harvard, Vancouver, ISO, and other styles

46

Pandey, Avinash, Desai Abhay, Jandyal Sunny, et al. "Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience." South Asian Journal of Cancer 05, no. 02 (2016): 059–62. http://dx.doi.org/10.4103/2278-330x.181627.

Full text

Abstract:

Abstract Background: Paclitaxel-platinum and optimal cytoreductive surgery are the standard of care for ovarian carcinoma. Poor socioeconomic profile and therapeutic constraints in rural India poses a therapeutic challenge. Aim: To evaluate outcomes of epithelial ovarian carcinoma. Objectives: To calculate disease-free survival (DFS), overall survival (OS), and factors affecting outcomes. Materials and Methods: Data of patients diagnosed as ovarian carcinoma registered between March 2009 and March 2014 were retrieved. Demographic profile, chemotherapy and response, surgery, and disease progres

APA, Harvard, Vancouver, ISO, and other styles

47

Koirala, Pratistha, Ashley S. Moon, and Linus Chuang. "Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction." Diagnostics 10, no. 8 (2020): 568. http://dx.doi.org/10.3390/diagnostics10080568.

Full text

Abstract:

Ovarian cancer is the deadliest gynecologic cancer, in part due to late presentation. Many women have vague early symptoms and present with disseminated disease. Cytoreductive surgery can be extensive, involving multiple organ systems. Novel therapies and recent clinical trials have provided evidence that, compared to primary cytoreduction, neoadjuvant chemotherapy has equivalent survival outcomes with less morbidity. There is increasing need for validated tools and mechanisms for clinicians to determine the optimal management of ovarian cancer patients.

APA, Harvard, Vancouver, ISO, and other styles

48

Aronson, Lot, Marta I. Lopez-Yurda, Simone N. Koole, et al. "Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up." Journal of Clinical Oncology 41, no. 16_suppl (2023): 5509. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5509.

Full text

Abstract:

5509 Background: The randomized, phase 3 OVHIPEC-1 trial (NCT00426257) investigated the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery in patients with stage III epithelial ovarian cancer who were ineligible for primary cytoreduction. OVHIPEC-1 previously demonstrated improved recurrence-free and overall survival after 4.7 years of follow-up. Here, we report the final survival outcomes after ten years of follow-up. In addition, we report new data on the subsequent anti-cancer treatments given after disease progression. Methods: Patients were ran

APA, Harvard, Vancouver, ISO, and other styles

49

Natalie, Shammas, Avila Rosa, Khatchadourian Christopher, Spencer-Smith Erland Laurence, Stern Lisa, and Vasilev Steven. "Minimally invasive cytoreductive surgery in advanced ovarian cancer: A nonselected consecutive series of robotic-assisted cases." Clinical Journal of Obstetrics and Gynecology 6, no. 2 (2023): 032–37. http://dx.doi.org/10.29328/journal.cjog.1001126.

Full text

Abstract:

The gold standard for advanced-stage ovarian cancer surgery entails exploration via a midline vertical laparotomy. Studies have shown that minimally invasive surgery (MIS) can be a safe and effective method for the surgical management of early ovarian cancer. In some cases, MIS can also be selectively used for cytoreductive surgery in cases with advanced-stage ovarian cancer. The robotic platform has the potential to provide similar outcomes to the laparotomy-based standard of care in advanced complex surgery while accelerating recovery, minimizing morbidity, and reducing perioperative complic

APA, Harvard, Vancouver, ISO, and other styles

50

Zang, R. Y., Z. T. Li, Z. Y. Zhang, and S. M. Cai. "Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: A retrospective case-control study." International Journal of Gynecologic Cancer 13, no. 4 (2003): 419–27. http://dx.doi.org/10.1136/ijgc-00009577-200307000-00004.

Full text

Abstract:

The objective of this paper is to clarify the role of cytoreductive surgery and salvage chemotherapy in the management of recurrent advanced epithelial ovarian carcinoma (RAEOC) and to identify factors affecting disease recurrence. One hundred sixty seven patients with RAEOC treated at the Cancer Hospital of Fudan University between January 1986 and December 1997 were retrospectively reviewed. Survival was calculated by Kaplan-Meier method with difference in survival estimated by the log-rank test. Independent prognostic factors were identified by the Cox stepwise regression model and variants

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!